Revolution Medicines, Inc.
RVMD
$149.94
$4.222.90%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 16.62% | 12.36% | |||
| Gross Profit | -16.62% | -12.36% | |||
| SG&A Expenses | 51.84% | 26.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.12% | 14.70% | |||
| Operating Income | -23.12% | -14.70% | |||
| Income Before Tax | -24.37% | -19.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -24.37% | -19.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -24.37% | -19.56% | |||
| EBIT | -23.12% | -14.70% | |||
| EBITDA | -23.23% | -14.73% | |||
| EPS Basic | -23.47% | -15.04% | |||
| Normalized Basic EPS | -23.47% | -15.04% | |||
| EPS Diluted | -23.47% | -15.04% | |||
| Normalized Diluted EPS | -23.47% | -15.04% | |||
| Average Basic Shares Outstanding | 0.73% | 3.93% | |||
| Average Diluted Shares Outstanding | 0.73% | 3.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||